# The Addition of Chloroquine to Chemoradiation for Glioblastoma

> **NCT02378532** · PHASE1 · COMPLETED · sponsor: **Maastricht Radiation Oncology** · enrollment: 13 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Chloroquine
- **RADIATION:** Radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02378532
- **Lead sponsor:** Maastricht Radiation Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-01-17
- **Final completion:** 2019-07-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378532, "The Addition of Chloroquine to Chemoradiation for Glioblastoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02378532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*